Journal of Autoimmunity

Papers
(The H4-Index of Journal of Autoimmunity is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases401
HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity227
Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats189
GILZ regulates type I interferon release and sequesters STAT1146
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination126
ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis125
Advances in SLE classification criteria110
The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial105
Editorial Board98
Differences in innate immune cell populations distinguish autoimmune from herpesvirus-associated encephalitis97
Global and regional epidemiology of psoriatic arthritis in patients with psoriasis: A comprehensive systematic analysis and modelling study96
Immunological and fibrotic profiling in the NOD.c3c4 murine model of autoimmune cholangitis93
Tfh cell-derived small extracellular vesicles exacerbate the severity of collagen-induced arthritis by enhancing B-cell responses90
Ectopic CD4+ T cells in choroid plexus mediate neuropsychiatric lupus symptoms in mice via interferon-γ induced microglia activation84
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients80
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations80
Lupus nephritis: new progress in diagnosis and treatment80
Breach of tolerance versus burden of bile acids: Resolving the conundrum in the immunopathogenesis and natural history of primary biliary cholangitis76
Autoimmune associated HLAs and T cell autoantigens exhibit common patterns across several autoimmune diseases76
Anti-annexin A4 antibody as a biomarker for desquamative interstitial pneumonia73
Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies70
Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus64
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort61
Identification of the central tolerance checkpoint for autoreactive proteinase 3+ B cells in human bone marrow60
Intracellular virus sensor MDA5 mutation develops autoimmune myocarditis and nephritis60
Cellular communication network factor 3 contributes to the pathological process of rheumatoid arthritis through promoting cell senescence and osteoclastogenesis in the joint60
Glycobiology of psoriasis: A review56
Editorial Board55
Sunscreen use associated with elevated prevalence of anti-nuclear antibodies in U.S. adults50
Editorial Board45
Editorial Board44
Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus43
Antigenic mimicry – The key to autoimmunity in immune privileged organs43
Assessment of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Chinese cohort: Impact on clinical practice41
Non-coding RNAs in immunoregulation and autoimmunity: Technological advances and critical limitations41
Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes41
Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formation41
FAPI PET/CT for tracking disease trajectory in myositis-related interstitial lung disease41
LAT1 enables T cell activation under inflammatory conditions39
0.14124894142151